logo

For the Inventor, By the Inventor

Antony, France

Emmanuel Nony

This inventor holds 29 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 13 EPO patents, primarily in Immunotherapy Biomarkers. Top assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Stallergenes, Lfb Biotechnologies. Active years: 2009-2021.

USPTO Granted Patents = 29 

% Patents Active = 48.3

 

 

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 120(Granted Patents)


Company Filing History:

goldMedal16 out of 97 
 
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
 patents
silverMedal6 out of 13 
 
Stallergenes
 patents
bronzeMedal5 out of 10 
 
Lfb Biotechnologies
 patents
4. 2 out of 5 
 
Stallergenes S.a.
 patents
5. 1 out of 1,853 
 
National Institute of Health and Medical Research
 patents
where one patent can have more than one assignee

Years Active: 2009-2021

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Immune Response
Biomarkers
Monoclonal Antibodies
ADCC Optimization
Immunotherapy Efficacy
Dendritic Cells
Recombinant Proteins
Inflammatory Diseases
Cancer Treatment
Glycosylation Sites
Allergen Diagnostics
Effector Cells
29 patents (USPTO):Explore Patents
1. 11015221 - Markers of immune response (2021-05-25),
2. 10884002 - Sialylated fetuin-A as a marker of immunotherapy efficacy (2021-01-05),
3. 10364425 - Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units (2019-07-30),
4. 10344272 - Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units (2019-07-09),
5. 10190166 - Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy (2019-01-29),
6. 10101341 - Biomarkers of immunotherapy efficacy (2018-10-16),
7. 10081683 - Monoclonal antibodies with enhanced ADCC function (2018-09-25),
8. 9879089 - Use of ADCC-optimized antibodies for treating low-responder patients (2018-01-30),
9. 9868770 - Recombinant Der P 2 expressed in Pichia Pastoris as a 'natural-like' allergen for immunotherapy and diagnostic purposes (2018-01-16),
10. 9822185 - Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa (2017-11-21),
11. 9718890 - Monoclonal antibodies with enhanced ADCC function (2017-08-01),
12. 9718889 - Monoclonal antibodies with enhanced ADCC function (2017-08-01),
13. 9708409 - Monoclonal antibodies with enhanced ADCC function (2017-07-18),
14. 9187568 - [object Object] (2015-11-17),
15. 9109020 - Use of ADCC-optimized antibodies for treating weak patients (2015-08-18),

Title: Inventor Emmanuel Nony

Introduction: Emmanuel Nony is a renowned inventor based in Antony, France, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Emmanuel Nony holds several patents in various technological domains, showcasing his continuous commitment to pushing the boundaries of innovation.

Career Highlights: With a career spanning over two decades, Emmanuel Nony has established himself as a visionary inventor, with a keen focus on developing solutions that have a tangible impact on society.

Collaborations: Throughout his career, Emmanuel Nony has collaborated with leading tech companies, research institutions, and universities to further his inventions and bring them to market, solidifying his reputation as a forward-thinker in the industry.

Conclusion: Emmanuel Nony's passion for innovation and his relentless drive to create have cemented his status as a prominent figure in the world of inventors, with his work continuing to inspire future generations of innovators.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…